Schedule 13D ownership disclosure
OnKure Therapeutics, Inc.
Common stock, par value $0.0001 per share · CUSIP: 68277Q105
Event date: 2025-05-15
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ACORN BIOVENTURES, L.P.Reported CIK 0001766853
Shares: 1,709,944.00 · Class: 13.3%
- ACORN CAPITAL ADVISORS GP, LLCReported CIK 0001813692
Shares: 1,709,944.00 · Class: 13.3%
- Anders Hove
Shares: 2,839,674.00 · Class: 22.1%
- ACORN BIOVENTURES 2, L.P.Reported CIK 0001876405
Shares: 1,129,730.00 · Class: 8.8%
- Acorn Capital Advisors GP 2, LLC
Shares: 1,129,730.00 · Class: 8.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001636587-25-000030
- Form type
- SCHEDULE 13D/A
- Filer
- ACORN BIOVENTURES, L.P.
- CIK
- CIK 1766853
- Filed
- May 30, 2025
- Reporting period
- May 15, 2025
- Description
- Schedule 13D beneficial ownership